Navigation Links
Watson Files FDA Application for Generic Mucinex(R) D
Date:6/10/2009

- Paragraph IV Litigation Underway -

CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its guaifenesin pseudoephedrine HCI extended-release 600mg/60mg and 1200mg/120mg tablets prior to the expiration of patents owned by Reckitt Benckiser Inc. Watson Laboratories, Inc. - Florida's guaifenesin pseudoephedrine HCI extended-release tablet products are the generic versions of Reckitt Benckiser Inc.'s Mucinex(R) D product, which are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. Watson Laboratories, Inc. - Florida previously filed ANDAs seeking approval to market generic versions of Reckitt Benckiser Inc.'s Mucinex(R) and Mucinex(R) DM products.

Reckitt Benckiser filed suit against Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc. - Florida on June 5, 2009 in the U.S. District Court for the Southern District of Florida seeking to prevent Watson from commercializing its products prior to expiration of U.S. patent numbers 6,372,252 and 6,955,821. Reckitt Benckiser's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson Laboratories, Inc. - Florida's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner. Based on available information, Watson Pharmaceuticals, Inc. believes that Watson Laboratories, Inc. - Florida may be the first applicant to file an ANDA for a generic version of Mucinex(R) D and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve-months ended March 31, 2009, Mucinex(R) D products had total U.S. sales of approximately $62 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Mucinex(R) D is a registered trademark of Reckitt Benckiser Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
2. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
3. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
4. Watson Files FDA Applications for Generic Mucinex(R)
5. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
6. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
7. Mark G. Watson Named Executive Director of Radiological Society of North America
8. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
9. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
10. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
11. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Medic ... Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal of Emergency ... at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, a ...
(Date:5/24/2017)... ... ... thinking of a visit to San Francisco , fall is a great time to ... , Business Architecture Associates is pleased to offer 5 days of training courses, available to ... for individuals, and as 4-½ day corporate package for up to 3 employees with the ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... Wisconsin (PRWEB) , ... May 24, 2017 , ... ... in clean label food ingredient solutions for the food and beverage industry offers ... in food ingredient statements during the purchasing decision process. As a result, labels ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... , May 4, 2017  A new ... thermoplastics and other highly-engineered materials, is being launched ... tubing has been developed in recent years to ... therapies and surgical applications. More expensive materials such ... produce microextrusion tubing due to their ability to ...
(Date:5/3/2017)... WAYNE, N.J. , May 3, 2017 /PRNewswire/ ... systems that contribute to quality enhancement and cost ... results from a study of contemporary practice demonstrating ... a first-line therapy for critically ill patients. The ... the Company,s newer large volume MEGA ® ...
Breaking Medicine Technology: